ATRX and neoplasm: An increased sensitivity of ATRX-altered tumour cells to DNA damage response (DDR) inhibitors targeting ATM54, WEE159, ATR and PARP60,61 has been reported in other neuroectodermal cancers, and therefore might be effective in PCPG.